SCHEMBL150570

SCHEMBL150570

CCN(CC)c1ccc(N)c(SS(=O)(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.58
L3MBTL1 Q9Y468 8/20 0.58
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
HPGD P15428 4/20 0.58
HSP90AA1 P07900 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
S100B P04271 1/20 0.50
MAPT P10636 5/20 0.43
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 2/20 0.41
PSMD14 O00487 1/20 0.41
TSHR P16473 1/20 0.41
RECQL P46063 1/20 0.41
GFER P55789 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TERT O14746 1/20 0.37
HSD17B10 Q99714 2/20 0.36
ALDH3A1 P30838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5512903 0.88 MEN1 (0.44) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL195345 0.87 MEN1 (0.45) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL743427 0.83 ALDH1A1 (0.39) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL127303 0.83 ALDH1A1 (0.39) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL179662 0.81 MEN1 (0.37) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL3971008 0.79 ALDH1A1 (0.50) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL10346490 0.76 S100B (0.54) ALDH1A1L3MBTL1MEN1KMT2AHPGD
Sulfuric Acid SCHEMBL7955346 0.76 S100B (0.80) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL150568 0.74 S100B (0.51) ALDH1A1L3MBTL1MEN1KMT2AHPGD
SCHEMBL150489 0.74 CTDSP1 (0.36) ALDH1A1L3MBTL1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11116772-B2 Medical methods utilising high purity diaminophenothiazinium compounds WISTA LABORATORIES LTD. (SG) 2021-09-14 US disclosed
US-11116772-B2 Medical methods utilising high purity diaminophenothiazinium compounds WISTA LABORATORIES LTD. (SG) 2021-09-14 US disclosed
US-20200268767-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS WISTA LABORATORIES LIMITED (SG) 2020-08-27 US disclosed
US-20200268767-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS WISTA LABORATORIES LIMITED (SG) 2020-08-27 US disclosed
EP-3564223-A1 METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) WisTa Laboratories Ltd. (SG) 2019-11-06 EP disclosed
EP-2322517-B1 METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) WISTA LAB LTD (SG) 2019-04-24 EP disclosed
US-20180078562-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS WISTA LABORATORIES LTD. (SG) 2018-03-22 US disclosed
US-20180078562-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS WISTA LABORATORIES LTD. (SG) 2018-03-22 US disclosed
US-20180078562-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS WISTA LABORATORIES LTD. (SG) 2018-03-22 US disclosed
EP-2004155-B1 INHIBITORS OF PROTEIN AGGREGATION WISTA LAB LTD (SG) 2018-02-21 EP disclosed
US-20080207603-A1 Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) WISTA LABORATORIES LTD. 2008-08-28 US disclosed
US-20080207603-A1 Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) WISTA LABORATORIES LTD. 2008-08-28 US disclosed
CN-101084204-A Methods for chemical synthesis and purification of diaminophenothiazinium compounds, including methylthioninium chloride (MTC) WISTA LAB LTD (SG) 2007-12-05 CN disclosed
WO-2007110629-A1 INHIBITORS OF PROTEIN AGGREGATION WISTA LABORATORIES LTD (SG) 2007-10-04 WO disclosed
WO-2007110630-A1 THIONINIUM COMPOUNDS AND THEIR USE WISTA LABORATORIES LTD. (SG) 2007-10-04 WO disclosed
EP-1799662-A2 METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) Wista Laboratories Ltd. (SG) 2007-06-27 EP disclosed
US-20060287523-A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) WISTA LABORATORIES LTD. (SG) 2006-12-21 US disclosed
WO-2006032879-A2 METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) WISTA LABORATORIES LTD. (SG) 2006-03-30 WO disclosed
WO-2006032879-A2 METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) WISTA LABORATORIES LTD. (SG) 2006-03-30 WO disclosed
US-4962197-A Photo-inactivation of cancer cells ROWLAND INSTITUTE FOR SCIENCE (US) 1990-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11116772-B2 Medical methods utilising high purity diaminophenothiazinium compounds MGMT, MAPT, TST ALDH1A1 3409/4885L3MBTL1 3969/4885MEN1 205/4885
US-20080207603-A1 Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) MGMT, MAPT, CRBN ALDH1A1 3952/4885L3MBTL1 1757/4885MEN1 45/4885
US-20060287523-A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) MGMT, MAPT, TST ALDH1A1 3877/4885L3MBTL1 3570/4885MEN1 128/4885
US-20180078562-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS MGMT, MAPT, TST ALDH1A1 3735/4885L3MBTL1 4142/4885MEN1 240/4885
US-20200268767-A1 MEDICAL METHODS UTILISING HIGH PURITY DIAMINOPHENOTHIAZINIUM COMPOUNDS MGMT, MAPT, TST ALDH1A1 3735/4885L3MBTL1 4142/4885MEN1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.